Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;24(10):663–669. doi: 10.1002/clc.4960241006

Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood

Diana Iarussi 1,✉, Maurizio Galderisi 1, Gennaro Ratti 1, Michele Adolfo Tedesco 1, Paolo Indolfi 2, Fiorina Casale 2, Maria Teresa Di Tullio 2, Oreste De Divitiis 3, Aldo Iacono 1
PMCID: PMC6655021  PMID: 11594412

Abstract

Background: In childhood, late cardiotoxicity is characterized by inappropriately thin wall and consequent increased end‐systolic wall stress, but the associations of impaired left ventricular geometry and function occurring under these circumstances need further investigation.

Hypothesis: The purpose of this study was to assess anthracycline late effects on the relationships occurring between increased end‐systolic stress (ESS) and changes in both M‐mode systolic measurements (i.e., endocardial and midwall fractional shortening) and Doppler diastolic indices in the pediatric age.

Methods: The population consisted of 101 children treated with anthracyclines for at least 12 months and 91 healthy children. Using M‐mode echocardiography, end‐systolic wall stress was calculated as index of afterload, and endocardial and midwall fractional shortening as systolic indices. Doppler transmitral measurements were made as diastolic indices.

Results: Patients treated with anthracyclines showed significantly lower relative wall thickness and left ventricular mass index, greater end‐systolic wall stress, reduced endocardial and midwall fractional shortening and peak E/A ratio, prolonged deceleration, and isovolumic relaxation times. Direct relationships were found between end‐systolic wall stress and both endocardial and midwall shortening. The use of midwall shortening in the relation showed a greater, but not significant increase (from 3 to 6%) in the proportion of patients with depressed systolic function than did endocardial shortening. In the anthracycline group, end‐systolic wall stress was also inversely related to relative wall thickness and directly to isovolumic relaxation time.

Conclusions: In childhood, reduced myocardial thickness and increased afterload explain much of systolic and diastolic dysfunction of late anthracycline toxicity. Midwall fractional shortening does not seem to add useful information for identifying subsets of children more prone to the development of heart failure.

Keywords: anthracyclines, cardiotoxicity, left ventricular mass, left ventricular function, Doppler echocardiography

Full Text

The Full Text of this article is available as a PDF (659.3 KB).

References

  • 1. Young RC, Ozols RF, Myers CE: The anthracycline antineoplastic drug. N Engl J Med 1981; 305: 139–153 [DOI] [PubMed] [Google Scholar]
  • 2. Tan CT, Tasaka H, Yu KR Murphy ML, Karnofsky DA: Daunomycin, an antitumor antibiotic in the treatment of neoplastic disease. Cancer 1967; 20: 333–353 [DOI] [PubMed] [Google Scholar]
  • 3. Lefrak EA, Pitha J, Rosenheim S, Gotlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302–314 [DOI] [PubMed] [Google Scholar]
  • 4. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM: Daunomycin‐induced cardiotoxicity in children and adults. Am J Med 1977: 62: 200–207 [DOI] [PubMed] [Google Scholar]
  • 5. Bristow MR: Pathophysiologic basis for cardiac monitoring in patients receiving anthracyclines In Anthracyclines: Current Status and New Developments, p. 255–271 (Eds. Crooke ST, Reich SD.). New York, NY: Academic Press, 1980. [Google Scholar]
  • 6. Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Saltan SE, Cohen H, Jaffe N: Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children. Cancer 1981; 47: 2810–2816 [DOI] [PubMed] [Google Scholar]
  • 7. Bu'Lock FA, Mott MG, Oakhill A, Martin RP: Early identification of anthracycline cardiomyopathy: Possibilities and implications. Arch Dis Child 1996; 75: 416–422 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Von Hoff DD, Layard M, Bacerzach SP, Hamlin RL: Risk factors for doxorubicin‐induced congestive heart failure. Ann Intern Med 1979; 91: 710–717 [DOI] [PubMed] [Google Scholar]
  • 9. Hausdorf G, Morf G, Beron G, Ertmann R, Winkler K, Landbeck G, Keck EW: Long term doxorubicin cardiotoxicity in childhood: Noninvasive evaluation of contractile state and diastolic filling. Br Heart J 1988; 60: 309–315 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Goorin AM, Chauvenet AR, Perez‐Atayde AR, Cruz J, McKone R, Lipshultz SE: Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990; 116: 144–147 [DOI] [PubMed] [Google Scholar]
  • 11. Steinherz U, Steinherz PG, Tan CTC, Heller G, Murphy ML: Cardiac toxicity 4–20 years after completing anthracyclines therapy. J Am Med Assoc 1991; 266: 1672–1677 [PubMed] [Google Scholar]
  • 12. Lipshultz SE, Colan SD, Gelber RD, Perez‐Atayade AR, Sallan SE, Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808–815 [DOI] [PubMed] [Google Scholar]
  • 13. Bu'Lock FA, Mott MG, Oakhill A, Martin RP: Left ventricular diastolic function after anthracycline chemotherapy in childhood: Relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995; 73: 340–350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Ewer MS, Ali MK, MacKay B: A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol 1984; 2: 112–117 [DOI] [PubMed] [Google Scholar]
  • 15. Shimuzu G, Hirota Y, Kita K, Kawamura K, Saito T, Gaasch WH: Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure‐overload hypertrophy. Circulation 1991; 83: 1676–1684 [DOI] [PubMed] [Google Scholar]
  • 16. Grossman W, Braunwald E, Mann E, McLaurin LP, Green LH: Contractile state of the left ventricle in man as evaluated from end‐systolic pressure‐volume relations. Circulation 1977; 56: 845–852 [DOI] [PubMed] [Google Scholar]
  • 17. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH: Assessment of left ventricular function by the midwall fractional shortening/end‐systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23: 1444–1451 [DOI] [PubMed] [Google Scholar]
  • 18. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH: Midwall left ventricular mechanics: An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93: 259–265 [DOI] [PubMed] [Google Scholar]
  • 19. Sahn DJ, DeMaria A, Kisslo J, Weyman A, for the Committee of M‐mode standardization of the American Society of Echocardiography : Recommendations regarding quantitation in M‐mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083 [DOI] [PubMed] [Google Scholar]
  • 20. Devereux RB, Reicheck N: Echocardiographic determination of left ventricular mass: Anatomic validation of the method. Circulation 1977; 55: 613–618 [DOI] [PubMed] [Google Scholar]
  • 21. Levy D, Savage DD. Garrison RJ, Anderson KM, Kannel WB, Castelli WP: Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987: 59: 956–960 [DOI] [PubMed] [Google Scholar]
  • 22. Reichek N, Wilson J, St. John Sutton M, Plappert TA, Goldberg S, Hirsfield JW: Noninvasive determination of left ventricular end‐systolic stress: Validation of the method and initial application. Circulation 1982; 65: 99–109 [DOI] [PubMed] [Google Scholar]
  • 23. Nishimura RA, Abel MD, Hatle LK, Tajik AJ: Assessment of diastolic function of the heart: Background and current applications of Doppler echocardiography (Part II: Clinical studies). Mayo Clin Proc 1989; 64: 181–204 [DOI] [PubMed] [Google Scholar]
  • 24. Appleton CP, Hatle LA, Popp RL: Relation of transmitral flow velocity patterns to left ventricular diastolic function: New insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988; 12: 426–440 [DOI] [PubMed] [Google Scholar]
  • 25. Galderisi M, Paolisso G, Tagliamonte MR, Alfieri A, Petrocelli A, de Divitiis M, Varricchio M, de Divitiis O: Is insulin action a determinant of left ventricular relaxation in uncomplicated essential hypertension? J Hypertens 1997; 15: 745–750 [DOI] [PubMed] [Google Scholar]
  • 26. Kakadekar AP, Sandor GGS, Fryer C, Wah Chan K, Rogers PC, Pritchard S, Popov R: Differences in dose scheduling as a factor in the etiology of anthracycline‐induced cardiotoxicity in Ewing sarcoma patients. Med Ped Oncol 1997; 28: 22–26 [DOI] [PubMed] [Google Scholar]
  • 27. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738–1743 [DOI] [PubMed] [Google Scholar]
  • 28. Anversa P, Kajstura J, Olivetti G: Myocyte death in heart failure. Curr Opin Cardiol 1996; 11: 245–251 [DOI] [PubMed] [Google Scholar]
  • 29. Steinherz LJ, Steinherz PG, Tan C: Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: A series of 15 patients. Med Pediatr Oncol 1995; 24: 352–361 [DOI] [PubMed] [Google Scholar]
  • 30. Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JT, Lipshultz SE: Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 545–550 [DOI] [PubMed] [Google Scholar]
  • 31. Steinherz LI, Graham T, Hurwitz R, Sondheimer HM, Scwartz RC, Shaffer EM, Sandor G, Benson L, Williams R: Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the children cancer study group. Pediatrics 1992; 89: 942–949 [PubMed] [Google Scholar]
  • 32. Pisacane C, Iarussi D, Buono S, Gualtieri S, Coppolino P, Iacono A: Clinical usefulness of quantitative two‐dimensional echocardiographic analysis of segmental kinesis of left ventricle in monitoring of patients with neoplasms treated with anthracyclines. G Ital Cardiol 1991; 21: 1259–1267 [PubMed] [Google Scholar]
  • 33. Ross J Jr: Afterload mismatch and preload reserve: A conceptual framework for the analysis of ventricular function. Progr Cardiovasc Dis 1976; 18: 225–264 [DOI] [PubMed] [Google Scholar]
  • 34. Borow KM, Green LH, Grossman W, Braunwald E: Left ventricular end‐systolic stress‐shortening and stress‐length relations in humans: Normal values and sensitivity to inotropic state. Am J Cardiol 1982; 50: 1301–1308 [DOI] [PubMed] [Google Scholar]
  • 35. Municinò A, de Simone G, Roman MJ, Cody RJ, Ganau A, Hahn RT, Devereux RB: Assessment of left ventricular function by meridional and circumferential end‐systolic stress/minor‐axis shortening relations in dilated cardiomyopathy. Am J Cardiol 1996; 78: 544–549 [DOI] [PubMed] [Google Scholar]
  • 36. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT: Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987; 9: 184–188 [DOI] [PubMed] [Google Scholar]
  • 37. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, Poleur H: Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118: 92–98 [DOI] [PubMed] [Google Scholar]
  • 38. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J: Prolongation of isovolumetric relaxation time assessed by Doppler echocardiography predicts doxorubicin‐induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20: 62–69 [DOI] [PubMed] [Google Scholar]
  • 39. Grossman W, McLaurin P: Diastolic properties of left ventricle. Ann Intern Med 1976; 84: 316–326 [DOI] [PubMed] [Google Scholar]
  • 40. Gaasch WH, Apstein CS, Levine HJ: Diastolic properties of the left ventricle In The Ventricle: Basis and Clinical Aspects, p. 143 (Eds. Levine HJ, Gaash WH.). Boston: Martinus Nijhoff Publishing, 1985. [Google Scholar]
  • 41. Gonsalvez M, van Rossmum GDV, Blanco MF: Inhibition of sodium‐potassium‐activated adenosine 5′‐triphosphatase and ion transport by adriamycin. Cancer Res 1979; 39: 257–261 [PubMed] [Google Scholar]
  • 42. Billingham ME, Mason JW, Bristow MR, Daniels JR: Anthracycline cardiotoxicity monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865–872 [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES